The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
General Updates | Latest real-world & clinical evidence with GPRC5D therapies: toxicity, safety & QoL
In this discussion, Francesco Maura, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, Joshua Richter, MD, Mount Sinai Medical Center, New York City, NY, Andrew Yee, MD, Massachusetts General Hospital Cancer Center, Boston, MA, and Carlyn Tan, MD, Memorial Sloan Kettering Cancer Center, New York, NY, review the current landscape of GPRC5D-targeted therapies in multiple myeloma, highlighting real-world data. The experts discuss key challenges, including toxicity management with talquetamab, and emphasize the importance of supportive care strategies, patient education, and dosing adjustments to improve tolerability to these agents. To conclude, the panel explores evolving treatment strategies, including combination regimens, bridging to CAR-T, and emerging trispecific antibodies, which may enhance efficacy, reduce toxicity, and further optimize patient outcomes in the coming years.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
